S. Ettenberg

发表

Ovarian Cancer Cell Lines that Overexpress erbB2 Apoptosis-inducing Ligand-mediated Apoptosis in Breast and ( Herceptin ) Enhances Tumor Necrosis Factor-related Down-Regulation of the erbB2 Receptor by Trastuzumab

P. Dennis, M. Nau, S. Lipkowitz, 2001 .

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates

S. Ettenberg, Kalli C Catcott, M. McShea, 2016, mAbs.

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

Birgit Schoeberl, Andrew L. Kung, David M. Livingston, 2010, Cancer cell.

Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

M. Nau, E. Russell, S. Lipkowitz, 1999, Cancer research.

Reversing LRP5‐Dependent Osteoporosis and SOST Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity

S. Ettenberg, Feng Cong, C. Halleux, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity

G. Weiss, S. Ettenberg, K. McGinness, 2022, PloS one.

The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells.

S. Lipkowitz, S. Ettenberg, M. Keane, 1996, Cancer research.

N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines

M. Birrer, J. Liu, M. Nau, 2004, Cell Death and Differentiation.

Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines

M. Nau, S. Lipkowitz, M. Cuello, 2000, Breast Cancer Research and Treatment.

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

R. Mosher, W. Sellers, P. Finan, 2010, Proceedings of the National Academy of Sciences.

Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b

M. Nau, S. Lipkowitz, S. Ettenberg, 2004, Oncogene.

Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.

A Ciechanover, A. Ciechanover, Y. Yarden, 1999, Molecular cell.

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

W. Sellers, Guizhi Yang, C. Kowal, 2014, mAbs.

BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved antitumor activity

G. Weiss, S. Ettenberg, K. McGinness, 2021, bioRxiv.

Cbl-b-dependent Coordinated Degradation of the Epidermal Growth Factor Receptor Signaling Complex*

Y. Yarden, M. Nau, A. Weissman, 2001, The Journal of Biological Chemistry.

Fas expression and function in normal and malignant breast cell lines.

E. Russell, S. Lipkowitz, S. Ettenberg, 1996, Cancer research.

An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.

W. Sellers, J. Gu, C. Arteaga, 2013, Cancer research.

Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.

S. Collins, C. Arteaga, Q. Sheng, 2013, Cancer research.

Therapeutics , Targets , and Chemical Biology Combination of Antibody That Inhibits Ligand-Independent HER 3 Dimerization and a p 110 a Inhibitor Potently Blocks PI 3 K Signaling and Growth of HER 2 þ Breast Cancers

S. Collins, C. Arteaga, Q. Sheng, 2013 .

Characterization of activating mutations of NOTCH3 in T cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies

P. Lemotte, J. Aster, T. Hu, 2016, Oncogene.

Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

P. Dennis, M. Nau, S. Lipkowitz, 2001, Cancer research.

cbl-b inhibits epidermal growth factor receptor signaling

M. Nau, S. Lipkowitz, S. Ettenberg, 1999, Oncogene.

Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.

W. Sellers, T. Hu, Vivien W. Chan, 2017, Cancer discovery.

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

M. Nau, S. Lipkowitz, M. Cuello, 2001, Gynecologic oncology.

cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors.

M. Nau, S. Lipkowitz, S. Ettenberg, 1999, Molecular cell biology research communications : MCBRC.

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

N. Munshi, P. Tassone, D. Chauhan, 2007, Blood.

Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines.

M. Nau, S. Lipkowitz, M. Cuello, 2000, Breast cancer research and treatment.

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

S. Steinberg, S. Hewitt, S. Swain, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages

J. Lehár, W. Sellers, J. Korn, 2015, PloS one.

Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma

N. Munshi, P. Richardson, N. Rashid, 2015, Leukemia.

The ras suppressor, RSU-1, enhances nerve growth factor-induced differentiation of PC12 cells and induces p21CIP expression.

M. Cutler, S. Ettenberg, L. Masuelli, 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Preclinical Antitumor Activity of a Novel Anti–c-KIT Antibody–Drug Conjugate against Mutant and Wild-type c-KIT–Positive Solid Tumors

Anu V. Connor, W. Sellers, K. Mansfield, 2018, Clinical Cancer Research.

cbl-3: a new mammalian cbl family protein

J. Penninger, M. Nau, S. Lipkowitz, 1999, Oncogene.

WW Domain HECT E3s Target Cbl RING Finger E3s for Proteasomal Degradation*

S. Fang, A. Weissman, S. Lipkowitz, 2003, Journal of Biological Chemistry.

An Activated ErbB 3 / NRG 1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

W. Hahn, M. Meyerson, H. Greulich, 2022 .

Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches

W. Sellers, S. Fawell, D. Stover, 2012 .

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

N. Munshi, A. Dzik-Jurasz, F. Giles, 2009 .